Abstract: The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The present invention relates to a veterinary pharmaceutical composition containing torasemide to be used for treating cardiac failure. The torasemide is administered in a daily dose of 0.02 mg/kg to 0.1 mg/kg during long-term treatment.

Abstract: The present invention provides methods and compositions for treating subjects suffering from a disorder associated with a nicotinic acetylcholine receptor (nAChR), methods for treating a subject having a disorder that would benefit from an increase in neural plasticity, and methods for modulating the plasticity of the primary visual cortex in subjects by modulating the expression, stability, and/or activity of Lynx1.

Abstract: Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino} acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2?) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino} acetic acid and/or a prodrug thereof which can be used to treat cancer.

Abstract: Described are compositions and methods for the treatment, prevention, or amelioration of a symptom of an airway disorder. In certain aspects, the airway disorder may be one characterized by one or more conditions, such as goblet cell metaplasia, lung tissue inflammation, increased airway hyperresponsiveness, mucus hyperplasia, decreased airway resistance, and increased production of pro-inflammatory cytokines. The compositions and methods may be useful for the treatment of an airway disorder such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), allergic disorders, pulmonary inflammatory diseases, pulmonary fibrosis, and/or interstitial lung diseases.

Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.

Abstract: The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.

Abstract: This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.

Abstract: The present invention relates to a topical formulation that enhances genital sensation and function of a patient and a method for enhancing genital sensation and function of a patient, the method comprising topically applying a formulation to the genital area of the patient. The topical formulation can be utilized by either male or female users. The topical formulation incorporates active compounds which function cooperatively to stimulate nerve activity, enhancing sensitivity, and facilitating tumescence in order to increase pleasure from physical stimulation and orgasms. It has incorporated various compounds that provide energy and support energy production in a cell, that stimulate nerve activity and sensitivity, that support blood flow and/or vasodilation to a bodily region, that support penetration and transport of active compounds, and that preserve the efficaciousness, effectively dilute, serve as a carrier.

Abstract: Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt % to about 1.0 wt % norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving. Also included herein is a method of treating a human in need of a reduction in intraocular pressure by administering an intranasal formulation that includes a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the human in need thereof. Also, the beneficial effects of known drugs for high IOP are improved by co-administration with norketotifen.

Abstract: The present invention relates to a pharmaceutical composition comprising levocetirizine. The invention relates specifically to a dry syrup formulation.

Abstract: Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

Abstract: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.

Abstract: The present invention relates a foamable otic pharmaceutical compositions comprising oil-in water emulsions which comprise an antibiotic agent and a propellant gas. The pharmaceutical compositions are administered to the ear as foam for treating ear disorders.

Abstract: This invention provides an oral veterinary pharmaceutical or nutraceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion further comprising at least one component selected from taste enhancers, odour enhancers, digestive enzymes and veterinary drugs.

Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.

Abstract: Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.

Abstract: Disclosed are methods for treating cancer such as a myeloid malignancy such as multiple myeloma in a human using EZH2 inhibitors in human populations having a translocation MMSET or a decreased level of a functional UTX protein or both.

Abstract: Described are combination therapies and metabolically-activated drug conjugates and their use in treating cancer in subjects.

Abstract: The present invention relates to a method for treating a subject with a cancer resistant to a chemotherapeutic drug comprising administering to said subject a therapeutically effective amount of prochlorperazine or its analog or metabolite, or a pharmaceutically acceptable salt thereof, in combination of the chemotherapeutic drug. The present invention also relates to a method for preventing cancer metastasis with the combination of prochlorperazine in combination of a chemotherapeutic drug.

Abstract: The invention relates to the methods for synthesis, chemical structure and in vivo and in vitro anticancer effects of a palladium complex([Pd(bpma) (barb)]X·H2O) with high anticancer activity.

Abstract: This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14+/DR? cells (e.g., CD14+/DR? monocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that change the ratio of CD14+/HLA-DR? cells to CD14+/HLA-DR+ cells as well as methods and materials for (a) identifying a mammal as being likely to experience an elevated level of CD14+/DR? cells (e.g., CD14+/DR? monocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that reduce the degree to which the mammal develops CD14+/DR? cells are provided.

Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.

Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.

Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

Abstract: Methods for treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol) are provided. Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.

Abstract: The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.

Abstract: Microbial keratitis is a sight threatening disorder and infections result in ocular pain, stromal destruction, corneal thinning and/or perforation, leading to vision loss, if untreated and the need for transplantation. Methods of treating bacterial infection of the cornea prophylactically or therapeutically in a subject, are provided according to aspects of the present invention which include administering an effective dose of glycyrrhizin, or a pharmaceutically acceptable salt, hydrate, solvate, ester, amide, isomer or derivative thereof characterized by anti-bacterial activity, to the subject.

Abstract: The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein.

Abstract: The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.

Abstract: Provided herein are therapeutic oligonucleotides that comprise at least one p-ethoxy backbone linkage but no more than 80% p-ethoxy backbone linkages. Provided herein are improved delivery systems for therapeutic oligonucleotides comprising a liposome that comprises neutral phospholipids and a p-ethoxy oligonucleotide that is entrapped in the liposome.

Abstract: Methods and compositions are presented for treating traumatic brain injury and complications of traumatic brain injury, including pulmonary complications and cerebral edema.

Abstract: Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.

Abstract: The present disclosure provides biophotonic hydrogels and methods useful in phototherapy. In particular, the biophotonic hydrogels of the present disclosure include N-Hydroxyethyl acrylamide (HEAA), and at least one chromophore, wherein the at least one chromophore is not fully photobleached after photopolymerization. The biophotonic hydrogels and the methods of the present disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and various other skin disorders.

Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The present invention is directed toward an article of apparel configured to deliver a bioabsorbable alloy to the skin of a wearer. In an embodiment, the apparel is a textile base layer and a delivery layer oriented to contact the skin of the wearer. The delivery layer is formed from a composition including a magnesium alloy. In another embodiment, the textile is formed of strands coated with the magnesium alloy composition. In still further embodiments, the strands are formed of the alloy. The apparel may be configured to release a therapeutically effective amount to the user.

Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.

Abstract: Provided herein are methods and composition for the treatment for macrophage-related disorders, for example through the use of biomarkers for selection of responders and treatment monitoring.

Abstract: The present invention relates to a pharmaceutical composition comprising granules which include an inert core coated with ferric citrate. The present invention also provides methods of manufacture thereof and methods of use thereof.

Abstract: The current invention is a broad-based remediation mechanism against MRFs and includes nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. In an embodiment, the current invention relates to mitigation of drug resistant bacteria from nosocomial infections, for example in hospitals and in food animals. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRFs- and Vancomycin-Resistant Enterococcus (VRE)-induced illnesses without compromising the balance of the beneficial flora in the abdomen. Also, the combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in remediation of important food-borne bacteria including the resistant types.

Abstract: Some embodiments of the present disclosure include an anesthetic/analgesic composition for preventing or treating infections of the skin or muscle, insect bites, bruises, contusions, lacerations, burns, and other inflammatory conditions, including arthritic pain of joints. The composition may include water; a member selected from the group consisting of ionic silver and nano-silver; a phospholipid; a di-glyceride; a mineral oil; a humectant; a curcuminoid; and optionally, menthol.

Abstract: The invention features enriched Hox11+ stem cell compositions and methods of preparing and using the same. In particular, the enriched Hox11+ stem cell composition can be used for treating medical conditions, diseases, or disorders, for transplantation and transplantation therapy, and for cellular, tissue, or organ repair or regeneration.

Abstract: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific cytolytic activity (SCA) of an immune cell comprising contacting an immune cell with an antigen and an antigen-independent pro-inflammatory agent is provided. A method for ex vivo expansion of antigen-specific CD8+ T-cells with enhanced specific cytolytic activity (SCA) comprising culturing the antigen-specific CD8+ T-cells in a suitable culture media comprising an amino acid. An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. A method of treating a subject suffering from an infectious or neoplastic disease with immuno therapy is described.

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

Abstract: The disclosure is directed to the use of nonviable pluripotent stem cells to improve age-related declines in tissue and organ function. In one aspect, nonviable pluripotent stem cells are used to improve cognition in a subject in need thereof. In another aspect, nonviable pluripotent stem cells are used to improve age-related cardiac dysfunction in a subject in need thereof. Administration of nonviable pluripotent stem cells provides a transient and safe form of heterochronic cellular transbiosis.

Abstract: A system and method for reducing the likelihood of GERD includes the modification of an individual's gut microbes in a manner that reduces, if not eliminates, the symptoms of GERD. Certain embodiments employ Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to render H. Pylori more susceptible to certain drugs, including antibiotics, thus addressing the antibiotic resistance otherwise experienced by treating H. Pylori with antibiotics.

Abstract: A method and system for treating non-alcoholic fatty liver disease (NAFLD) involves the modulation of the gut microbial of a person suffering from NAFLD, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, TNF-? and to improve insulin resistance in NAFLD patients.

Abstract: Gut health in poultry is improved by providing an efficacious amount of extracts of tannic acid via feed or via drinking water. The extracts of tannic acid are also effective when the poultry are infected with coccidiosis and/or necrotic enteritis. In alternative embodiments, an efficacious amount of Bacillus coagulans is also included.